Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Ketamine Clinics Los Angeles Anticipates Landmark FDA Decision on MDMA-Assisted Therapy for PTSD


News provided by

Ketamine Clinics Los Angeles

Aug 08, 2024, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Ketamine Clinics Los Angeles: Pioneering Hope
Ketamine Clinics Los Angeles: Pioneering Hope

Industry Leader Weighs in on Potential Implications for Mental Health Treatment Landscape

LOS ANGELES, Aug. 8, 2024 /PRNewswire-PRWeb/ -- As the mental health community awaits a potentially groundbreaking decision from the U.S. Food and Drug Administration (FDA) on MDMA-assisted therapy for Post-Traumatic Stress Disorder (PTSD), Ketamine Clinics Los Angeles (KCLA), a pioneer in innovative mental health treatments, offers its perspective on the far-reaching implications of this ruling.

With the FDA's decision expected by August 11, KCLA's Co-founder and CEO, Sam Mandel, has shared a statement addressing the potential impact on mental health care, treatment accessibility, and the future of psychedelic medicine.

Regardless of the FDA's decision, we anticipate that this moment will spark increased public awareness of the exciting research on psychedelic therapies.

Post this

"As we approach the FDA's decision on MDMA-assisted therapy for PTSD, anticipated by August 11, we at Ketamine Clinics Los Angeles (KCLA) recognize the profound implications this ruling will have on the landscape of mental health treatment. As pioneers in Ketamine Infusion Therapy since 2014, we've witnessed firsthand the transformative potential of innovative approaches in addressing complex mental health challenges.

"The FDA's decision, regardless of the outcome, will undoubtedly influence the future of psychoactive treatments in mental health care. Should MDMA-assisted therapy receive approval, it would mark a significant milestone in the acceptance of psychedelics as legitimate medicines. This could pave the way for broader acceptance of ketamine therapy and other promising treatments, potentially increasing access for patients who have not found relief through traditional methods.

"An approval could also prompt necessary adaptations in regulatory frameworks to better accommodate treatments that combine pharmacology with psychotherapy. At KCLA, we've long recognized the value of this integrated approach, as evidenced by our comprehensive care model that includes Ketamine Infusion Therapy, preparation and integration, psychiatric evaluations and medication management, Transcranial Magnetic Stimulation (TMS), and other evidence-based innovations.

"However, if the FDA decides not to approve MDMA-assisted therapy, it may underscore the importance of established treatments like ketamine infusions, which already have FDA approval for certain indications and are utilized off-label for various mental health conditions. Ketamine's safety profile and efficacy in treating conditions such as PTSD, depression, anxiety, suicidality, and others, could be viewed even more favorably in this scenario.

"For the 13 million Americans suffering with PTSD, 40-60% of whom do not benefit from current first-line therapies, the decision is significant. An approval could lead to increased treatment options and reduced stigma surrounding psychedelic medicines. A rejection, while disappointing for many, could refocus attention on well-established solutions that are underfunded and underutilized, like ketamine infusions.

"Regardless of the FDA's decision, we anticipate that this moment will spark increased public awareness of the exciting research on psychedelic therapies. At KCLA, we will continue to offer our patients the highest standard of care, leveraging our decade of experience and our multidisciplinary team's expertise to provide evidence-based, personalized, comprehensive mental health care.

"As we await the decision, we stand ready to adapt and evolve our practices to best serve our patients and the broader mental health community. We encourage ongoing dialogue and collaboration among all stakeholders, including but not limited to healthcare providers, researchers, Indigenous leaders, advocacy groups, investors, media, and policymakers to ensure continued strides in improving mental health outcomes for all."

ABOUT KETAMINE CLINICS LOS ANGELES

Ketamine Clinics Los Angeles (KCLA), founded in 2014 by Dr. Steven L. Mandel and Sam Mandel, is a world-renowned pioneer in Ketamine Infusion Therapy and comprehensive mental health care. Operating from a state-of-the-art 5,000-square-foot healing center in Los Angeles, KCLA is the first and only ketamine clinic accredited by Quad A. With over 30,000 infusions administered and more than 6,000 patients treated, KCLA boasts an 83% success rate in treating various mental health conditions, including depression, anxiety, PTSD, and chronic pain. The clinic's multidisciplinary team, led by board-certified psychiatrists and specialized medical professionals, offers personalized treatment plans incorporating Ketamine Infusion Therapy, Psychiatric Medication Management, and Transcranial Magnetic Stimulation (TMS). KCLA's commitment to innovation, accessibility, and patient-centered care has established it as a leader in modern mental health treatment.

Media Contact
Brad Burge, Ketamine Clinics Los Angeles, 1 6508636887, [email protected], https://ketamineclinics.com

SOURCE Ketamine Clinics Los Angeles

Modal title

Sam Mandel, CEO and co-founder of Ketamine Clinics Los Angeles
Sam Mandel, CEO and co-founder of Ketamine Clinics Los Angeles
Sam Mandel, CEO and co-founder of Ketamine Clinics Los Angeles

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.